Colchicine and benzathine penicillin in the treatment of Behçet disease: A case comparative study

Dermatology Online Journal

Volumn 11, Issue 3, 2005, Pages

  Al Waiz, Makram M ^a   Sharquie, Khalifa E ^a   A Qaissi, Mohammed H ^a   Hayani, Raafa K ^a  

^a UNIVERSITY OF BAGHDAD   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATHINE PENICILLIN; COLCHICINE; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BEHCET DISEASE; CALCULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; RATING SCALE; RELAPSE; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; TABLET FORMULATION; TIME SERIES ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; MIDDLE AGED;

ADULT; ANTI-BACTERIAL AGENTS; BEHCET SYNDROME; COLCHICINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLIN G, BENZATHINE;

EID: 33746797805     PISSN: 10872108     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Sharquie KE. Behçet's disease. Postgraduate Doctor Middle East 1990; 13:186-190.
2. Jayashri V, Ghate JV, and Jorrizo JL. Behçet's disease and complex aphthosis. J Am Acad Dermatol 1999; 40:1-20.
3. Aoki K, Ohno S. Studies on the constitution and past history of patients with Behçet's disease. Acta Soc Ophthalmol J ph 1972; 76:1608-12.
4. Mizushima Y, Matsuda T, Hoshi K. Induction of Behçet's disease symptoms following dental treatment and streptococcal antigen skin test. J Rheumatol 1988; 15: 1029-30.
5. Isogai E, Isogai H, Yoshikawa K. Microbial Ecology of oral flora in BD. 5th International Conference on BD (abstract) 1989.
6. Jorizzo JL, Hudson RD, Schmalstieg FC. Behçet's syndrome: immune regulation, circulating immune complexes, neutrophil migration, and colchicine therapy. J Am Acad Dermatol 1984; 10: 205-14.
7. Bang D. Treatment of Behçet's disease. Yonsei Medical Journal 1997; 18: 401-410.
8. Jorizzo JL. Behçet's disease. In Fitzpatric Dermatology in General Medicine. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Kotz SI, Fitzpatric TB. 5th edition 1999 Vol. II Chapter 193: 2161-2165.
9. Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. A possible mechanism of treatment of dermatitis herpetiformis. J Clinic Invest 1978; 62:214.
10. Hamuryudan V, Mat C, Saip S. Thalidomide in the treatment of the mucocutaneous lesions of Behçet's syndrome: a randomized double cross D sign blind placebo controlled trial. Ann Intern Med 1998; 128:443- 50.
11. Jorizzo JL, White WL, Wise CM, et al. Low-dose weekly methotrexate for usual vascular reaction: cutaneous polyarteritis nodosa and Behçet's disease. J Am Acad Dermatol 1991; 24: 973-8.
12. Wahba A, Cohan H. Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol (Stockh) 1980; 60:515-30.
13. Kaidbey KH, Petrozzi JW, Kligman AM. Topical colchicine therapy for recalcitrant psoriasis. Arch Dermatol 1975; 111:33-6.
14. Seidman P, Fiellner B, Johannesson A. Psoriasis arthritis treated with oral colchicine. J Rheumatol 1987; 14:777-9.
15. Katz J, Langevitz P, Shemer J. Prevention of recurrent aphthous stomatitis with colchicine: an open trial. J Am Acad Dermatol 1994; 31:459-61.
16. Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol 1985; 13:193-200.
17. Mandell GL, Petri WA. Antimicrobial Agents: Penicillins, Cephalosporins,and other B-lactam antibiotics. In:Goodman &Gilman's. The Pharmacological Basis of Therapeutics . 9th edition. The Mc Graw- Hill Companies, 1996. CD-ROM.
18. Mary J, Richard A, Pamela C. Lippincott's Illustrated Reviews: Pharmacology.2nd edition .Philadelphia,Lippincott Williams &Wilkins,2000: 297-303.
19. Sharquie KE, Najim RA, Abu-Raghif AR. Treatment of Behçet's disease with dapsone: a double blind / placebo controlled clinical trial. In: Bang D, Lee ES, and Lee S, eds. Proceeding of the 8th and 9th international conference on Behçet's disease, 2001: P 468-73.
20. Sharquie KE, Najim RA and Abu- Raghif AR. Dapsone in Behçet's disease: a double cross D signblind, placebo cross D sign controlled, cross- over study. J Dermatol 2002; 29: 267-79.
21. Dilsen N, Konice M, Aral O. The importance of positive skin pathergy test in the diagnosis of Behçet's disease. In: Hamza M, editor. Proceding of 3rd Mediterranean Congress of Rheumatology, Tunis, Behçet's disease, 1986.
22. kunel RW, Duncan G, Watson D. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316:1562-8.
23. Boruchow IB. Bone marrow depression associated with acute colchicine toxicity in the presence of hepatic dysfunction. Cancer 1966; 19:541-3.
24. Naidus RM, Redvien R, Mieke CH Jr. Colchicine toxicity: a multi-system disease. Arch Intern Med 1977; 137:394-6.
25. Insel PA. Analgesic-Antipyretic and Anti inflammatory Agents and Drugs employed in the Treatment of Gout:colchicine. In: Googman &GilmanÕs. The Pharmacological Basis of Therapetics. 9th edition. The Mc Graw- Hill Companies, 1996.CD-ROM.
26. Isogai E, Isogai H, Yoshikaea K, Microbial Ecology of oral flora in BD. 5th International conference on BD(abstract) 1989.